Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 3 26Phase 1 12Phase 1/2 11Phase 4 5Phase 2/3 3Phase NA 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 4Caucasian Patients With EGFR Mutation Positive Advanced NSCLC 1Carcinoma 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Gefitinib × Clear all
NCT03264794 2017-08-29

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Jiangsu Famous Medical Technology Co., Ltd.

Phase 4 Unknown
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01203917 2017-01-02

IFUM

AstraZeneca

Phase 4 Completed
1,060 enrolled 14 charts
Thoracic

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

NCT00770588 2016-02-08

INFORM

AstraZeneca

Phase 4 Completed
296 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00536107 2013-10-01

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

AstraZeneca

Phase 4 Terminated
14 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00608868 2012-09-28

SELINE

AstraZeneca

Phase 4 Completed
156 enrolled 14 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡